The Shift!

The Shift!

It’s finally happening! Can you feel it?

When I started Caritas BioScience 6 years ago, it felt like neuroscience research was taking a real hit. I started the company in April 2017 and if memory serves me, I was only a couple of months in when GSK announced they were pulling out of their neuroscience pipeline. Followed over the next couple of years by other similar Pharma giants.

Having chosen to specialise in neurology, I must admit there was many an occasion when I wondered if I was making a huge mistake. It was a real shock to the system coming from a background in oncology where the ecosystem of developing new treatments was standard practice but I knew that it was such a huge area of unmet need that sooner or later there would have to be a breakthrough.

And it seems the time has come. The good news over the last couple of weeks with the approval of Eisai U.S. Neurology and Biogen ’s Lecanemab and yesterday’s announcement from 礼来 re Donanemab to me signal the start of a new era.

Though there’s a long way to go, hopefully these developments will give investors some confidence and subsequently patient’s some hope.

I am so proud to be a part of that journey and to contribute to our collective knowledge and understanding going forward and excited to see what comes next.

Pictured: My late grandfather who lived with Alzheimer's Disease